SpaceX Insider Share Sale Values Company Near $800 Billion Amid IPO Speculation 
Intel’s Testing of China-Linked Chipmaking Tools Raises U.S. National Security Concerns 
Strategy Retains Nasdaq 100 Spot Amid Growing Scrutiny of Bitcoin Treasury Model 
SpaceX Edges Toward Landmark IPO as Elon Musk Confirms Plans 
Trello Outage Disrupts Users as Access Issues Hit Atlassian’s Work Management Platform 
Gold Prices Slip Slightly in Asia as Silver Nears Record Highs on Dovish Fed Outlook 
ASX Shares Slide After ASIC Imposes A$150 Million Capital Requirement 
Ireland Limits Planned Trade Ban on Israeli Settlements to Goods Only 
California Jury Awards $40 Million in Johnson & Johnson Talc Cancer Lawsuit 
Rio Tinto Signs Interim Agreement With Yinhawangka Aboriginal Group Over Pilbara Mining Operations 
Wall Street Futures Dip as Broadcom Slides, Tech Weighed Down Despite Dovish Fed Signals 
S&P 500 Slides as AI Chip Stocks Tumble, Cooling Tech Rally 
Oil Prices Rebound as U.S.-Venezuela Tensions Offset Oversupply Concerns 
Dollar Struggles as Markets Eye Key Central Bank Decisions and Global Rate Outlooks 
Indonesia–U.S. Tariff Talks Near Completion as Both Sides Push for Year-End Deal 
Fed’s Dovish Tone Sends Dollar Lower as Markets Price In More Rate Cuts 
South Korea Extends Bond Market Stabilization Measures Amid Rising Financial Risks 
Celltrion, a South Korean pharmaceutical company, formulated a COVID-19 antibody treatment, and it is reportedly ready to deliver the drug to the United States and Europe. With its new treatment, the company has now made the world’s third drug for coronavirus.
Now it is likely to enter the European and U.S. markets before this year ends, as per The Korea Herald. This information was revealed in a report that was released on Monday, Aug. 23.
Lee Dong Geon, an analyst at Shinhan Investment, said that Celltrion will be applying for the issuance of emergency use authorization for its Regkirona COVID-19 antibody treatment. It is hoped that the US Food and Drug Administration will approve this drug that is also called the CT-P59 for EUA.
Moreover, it was predicted that it would not be long until Celltrion’s Regkirona is approved. In fact, it may be out in the U.S. market as early as the fourth quarter of this year. As for the EU market, it was estimated that it could obtain regulatory approval from the Europen Medicine Agency before October since it is already under review.
Apparently, once Celltrion succeeded in rolling out Regkirona in the U.S. and Europe, the company’s position in the pharmaceutical business will surely improve, and this will be felt and observed in the coming months.
In any case, Rekirona is an antibody treatment for coronavirus, and it is the first drug to be developed by Celltrion. It already received a green light from South Korea, Indonesia, and recently, in Brazil. The pharma firm said that as soon as the EMA gives its approval, it will immediately ship the drug to the EU.
Celltrion said that this treatment could shorten the number of treatment days for patients with COVID-19. What’s more, it could also prevent the condition of patients from getting severe.
Meanwhile, as soon as the news of Celltrion’s possible shipment of Regkirona to major markets in the world, Pulse News reported that the company’s shares soared, gaining 6.77 percent to close at ₩284,000 or around $241.97 on Kospi. It was added that it finished 8.21 percent higher and Celltrion Healthcare also went up by 7.94 percent.
